Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Company overview Novartis pipeline in Phase 1 Oncology Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Code Name Solid tumors AAA603 177Lu-NeoB Mechanism AAA604 AAA604 AAA614 AAA614 AAA802 225AC-PSMA-R2 225AC-PSMA-617 AAA817 HRO761 HRO761 IAG933 IAG933 KFA115 KFA115 MGY825 MGY825 NZV930 NZV930 QEQ278 QEQ278 Hematology DFV890 DFV890 PIT565 PIT565 Radioligand therapy target GRPR Radioligand therapy target integrin beta-3/beta-5 Radioligand therapy target FAP Radioligand therapy target PSMA Radioligand therapy target PSMA Werner inhibitor Novel immunomodulatory Agent CD73 antagonist NKG2D/-L pathway modulator NLRP3 inhibitor YTB323 rapcabtagene autoleucel CD19 CAR-T Indication(s) Multiple solid tumors Breast cancer Glioblastoma multiforme Pancreatic cancer Solid tumors Prostate cancer Metastatic castration-resistant prostate cancer Solid tumors Mesothelioma Solid tumors NSCLC Solid tumors Solid tumors Low risk myelodysplastic syndrome B-cell malignancies Adult ALL Cardiovascular, Renal and Metabolic Code Name DFV890 DFV890 Mechanism NLRP3 inhibitor Indication(s) Cardiovascular risk reduction □ NOVARTIS Reimagining Medicine Neuroscience Code Name DFT383 DFT383 NIO752 NIO752 Mechanism CTNS gene delivery Tau antisense oligonucleotide Immunology INNOVATION 17 lead indications Lead indication Indication(s) Cystinosis pre/post kidney transplant Alzheimer's disease Progressive supranuclear palsy Code Name MHV370 MHV370 Mechanism Indication(s) TLR7, TLR8 Antagonist Systemic lupus erythematosus Others Code Name Mechanism Indication(s) IB&GH EDI048 EDI048 EYU688 EYU688 INE963 INE963 CpPI(4)K inhibitor NS4B inhibitor Cryptosporidiosis Dengue Malaria, uncomplicated Novartis Q4 Results | January 31, 2024 38

View entire presentation